EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

ROX (Respiratory rate–OXygenation) index to predict early response to high‐flow nasal cannula therapy in infants with viral bronchiolitis

Christophe Milesi iD, Erika Nogue, Julien Baleine, Lionel Moulis, Robin Pouyau, Arthur Gavotto, David Brossier, Guillaume Mortamet, Gilles Cambonie, GFRUP Respiratory Study Group

Pediatric Pulmonology · 2024-04 · 59 (4) · 982-990

DOI: 10.1002/ppul.26860 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Pulmonology, online erschienen am 10.01.2024. Verfasst von Christophe Milesi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Intensive Care Unit, Arnaud de Villeneuve University Hospital, Montpellier, France. Hauptthemen laut MEDLINE: Bronchiolitis, Viral, Bronchiolitis, Pneumonia, Respiratory Distress Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

High‐flow nasal cannula (HFNC) is commonly used as first step respiratory support in infants with moderate‐to‐severe acute viral bronchiolitis (AVB). This device, however, fails to effectively manage respiratory distress in about a third of patients, and data are limited on determinants of patient response. The respiratory rate–oxygenation (ROX) index is a relevant tool to predict the risk for HFNC failure in adult patients with lower respiratory tract infections. The primary objective of this study was to assess the relationship between ROX indexes collected before and 1 h after HFNC initiation, and HFNC failure occurring in the following 48 h in infants with AVB.

Method

This is an ancillary study to the multicenter randomized controlled trial TRAMONTANE 2, that included 286 infants of less than 6 months with moderate‐to‐severe AVB. Collection of physiological variables at baseline (H0), and 1 h after HFNC (H1), included heart rate (HR), respiratory rate (RR), fraction of inspired oxygen (FiO 2 ), respiratory distress score (modified Wood's Clinical Asthma Score [mWCAS]), and pain and discomfort scale (EDIN). ROX and ROX‐HR were calculated as and , respectively. Predefined HFNC failure criteria included increase in respiratory distress score or RR, increase in discomfort, and severe apnea episodes. The accuracies of ROX, ROX‐HR indexes and clinical variable to predict HFNC failure were assessed using receiver operating curve analysis. We analyzed predictive factors of HFNC failure using multivariate logistic regressions.

Result

HFNC failure occurred in 111 of 286 (39%) infants, and for 56 (50% of the failure) of them within the first 6 h. The area under the curve of ROX indexes at H0 and H1 were, respectively, 0.56 (95% confidence interval [CI] 0.48–0.63, p = 0.14), 0.56 (95% CI 0.49–0.64, p = 0.09). ROX‐HR performances were better but remained poorly discriminant. HFNC failure was associated with higher mWCAS score at H1 ( p < 0.01) and lower decrease in EDIN scale during the first hour of HFNC delivery ( p = 0.02). In the multivariate analyses, age and mWCAS score were were found to be independent factors associated with HFNC failure at H0. At H1, weight and mWCAS were associated factors.

Conclusion

In this study, neither ROX index, nor physiological variables usually collected in infants with AVB had early discriminatory capacity to predict HFNC failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchiolitis, ViralBronchiolitisPneumoniaRespiratory Distress SyndromeRespiratory InsufficiencyInfantAdultHumansCannulaRespiratory RateOxygen Inhalation TherapyDyspnea

Stichwörter der Autor:innen

bronchiolitisfailurehigh‐flow nasal cannulainfantrisk prediction

Autor:innen und Institutionen

  • Pediatric Intensive Care Unit, Arnaud de Villeneuve University Hospital, Montpellier, France.
  • Clinical Research and Epidemiology Unit, CHU Montpellier, Univ Montpellier, Montpellier, France.
  • Pediatric Intensive Care Unit, Woman-Mother-Child University Hospital, Lyon, France.
  • Pediatric Intensive Care Unit, University Hospital Caen-Normandy, France.
  • Pediatric Intensive Care Unit, Grenoble University Hospital, La Tronche, France.

ORCID-Profile: Christophe Milesi

Förderung

  • None

Zitieren

APA

Milesi, C., Nogue, E., Baleine, J., Moulis, L., Pouyau, R., Gavotto, A., Brossier, D., Mortamet, G., Cambonie, G., & GFRUP Respiratory Study Group (2024). ROX (Respiratory rate–OXygenation) index to predict early response to high‐flow nasal cannula therapy in infants with viral bronchiolitis. Pediatric Pulmonology, 59(4), 982-990. https://doi.org/10.1002/ppul.26860

Vancouver

Milesi C, Nogue E, Baleine J, Moulis L, Pouyau R, Gavotto A, et al. ROX (Respiratory rate–OXygenation) index to predict early response to high‐flow nasal cannula therapy in infants with viral bronchiolitis. Pediatric Pulmonology. 2024;59(4):982-990. doi:10.1002/ppul.26860

BibTeX
@article{Milesi2024,
  author = {Milesi, Christophe and Nogue, Erika and Baleine, Julien and Moulis, Lionel and Pouyau, Robin and Gavotto, Arthur and Brossier, David and Mortamet, Guillaume and Cambonie, Gilles and GFRUP Respiratory Study Group, GFRUP Respiratory Study Group},
  title = {ROX (Respiratory rate–OXygenation) index to predict early response to high‐flow nasal cannula therapy in infants with viral bronchiolitis},
  journal = {Pediatric Pulmonology},
  year = {2024},
  volume = {59},
  number = {4},
  pages = {982--990},
  doi = {10.1002/ppul.26860}
}
Kostenlos starten →